Lymphoedema is a well-known and quality-of-life lowering side effect of breast cancer treatment, particularly for women who undergo axillary lymph node dissection. Epidemiological and self-reported data suggest that Black women may be at increased risk of developing breast cancer related lymphoedema after axillary lymph node dissection, albeit that prospective clinical data is lacking. Dr Andrea Barrio (Memorial Sloan-Kettering Cancer Center, NY, USA) presented results from a prospective study investigating the impact of race and ethnicity on breast cancer related lymphoedema incidence and severity [1].
The study enrolled 304 patients and included 276 patients who had at least one longitudinal measurement after baseline included in the analysis. Sixty percent of the participants were White; 20% were Black; 11% were Asian; and 6% were Hispanic (3% did not report race or ethnicity). Black women were older (P=0.007), had higher baseline BMI (P<0.001), and were more likely to be clinically node-positive (P=0.016) compared to White, Asian, and Hispanic women. Both black and Hispanic women were more likely to undergo breast-conserving surgery (P=0.037) and receive nodal radiotherapy (P=0.02). Breast cancer-related lymphoedema was defined as a relative volume change of 10% or greater from baseline.
At a median follow-up of 1.6 years, 50 women developed breast cancer-related lymphoedema. The 24-month breast cancer-related lymphoedema rate was 20.5% for White women, 23.4% for Asian women, 27.7% for Hispanic women, and 39.4% for Black women (see Figure). Multivariate analysis showed that Black race was the strongest predictor of breast cancer-related lymphoedema development (OR 3.53; P<0.001) versus White women as reference category. Hispanic ethnicity was also associated with a higher incidence of breast cancer-related lymphoedema (OR 3.11). However, the number of Hispanic patients included was low. In addition, neoadjuvant chemotherapy was associated with a 2-fold increase (OR 2.07; P=0.017) of breast cancer-related lymphoedema incidence. Among patients with lymphoedema, there was no difference in lymphoedema severity across racial and ethnic groups, with similar relative volume changes observed.
Figure: Cumulative Incidence of Lymphedema by race/ethnicity [1].

“The aetiology for the higher observed incidence of lymphoedema in Black women is unknown,” said Dr Barrio. “It may be due to race-based differences in inflammatory reaction, tissue fibrosis, and lymphatic function. Future studies should address the biologic mechanisms behind racial disparities in lymphoedema development and develop possible preventive strategies.”
In addition, analysis of the data from the I-SPY trial (NCT01042379) showed that race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response (OR relative to White: 1.00 for Asian and 0.89 for Black) and event-free survival (HR relative to White: 1.10; P=0.73 for Asian and 1.37; P=0.13 for Black) [2].
- Montagna G, et al. Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study. GS4-01, SABCS 2021 Virtual Meeting, 7–10 December.
- Kyalwazi B, et al. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial. GS4-02, SABCS 2021 Virtual Meeting, 7–10 December.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection Next Article
Olaparib is well tolerated as an additional treatment »
« Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection Next Article
Olaparib is well tolerated as an additional treatment »
Table of Contents: SABCS 2021
Featured articles
Early-Stage Breast Cancer
Aromatase inhibitors outperform tamoxifen in premenopausal women
Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer
Reduced risk of recurrence with ovarian suppression plus tamoxifen/exemestane
Metformin does not improve outcomes in patients with early-stage breast cancer
Omitting sentinel lymph node biopsy improves arm symptoms
HR-positive/HER2-negative Breast Cancer
Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment
The SERD elacestrant improves outcomes for patients unresponsive to endocrine therapy
Consistent overall survival benefit of ribociclib in advanced breast cancer
Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy
Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant
ctDNA is prognostic and predictive for response to ribociclib plus letrozole
Early switch to fulvestrant plus palbociclib beneficial for patients with ESR1 mutation
Triple-Negative Breast Cancer
Single-cell spatial analysis can predict response to neoadjuvant immunotherapy
Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC
Early use of ctDNA testing can identify likelihood of relapse in TNBC
Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10
Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity
Phase 1–3 Trials
Datopotamab deruxtecan shows promising anti-tumour activity
Trastuzumab deruxtecan outperforms trastuzumab emtansine
Nivolumab plus ipilimumab serve promising dual checkpoint inhibition
Entinostat plus exemestane improves progression-free survival in Chinese patients
Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients
Basic and Translational Research
Using genomics to match treatments improves outcomes
Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors
Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells
MAPK-pathway alterations are associated with resistance to anti-HER2 therapy
Genomic signatures of DCIS define biology and correlate with clinical outcomes
BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy
Miscellaneous
Olaparib is well tolerated as an additional treatment
Race effects the likelihood to develop lymphoedema following breast cancer treatment
Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection
One in 7 breast cancers detected during screening are overdiagnosed
Related Articles

September 23, 2020
ESMO 2020 Highlights Podcast

January 20, 2022
CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy